BPSR
Organicell Regenerative Medicine, Inc. [BPSR] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
BPSR Stock Summary
In the News
BPSR Financial details
Company Rating
Neutral
Market Cap
0
Income
-16.96M
Revenue
4.91M
Book val./share
-0
Cash/share
0
Dividend
-
Dividend %
-
Employees
18
Optionable
No
Shortable
Yes
Earnings
-
P/E
-3.2
Forward P/E
-
PEG
-0.17
P/S
-
P/B
-28.92
P/C
-
P/FCF
-
Quick Ratio
0.24
Current Ratio
0.33
Debt / Equity
-0.23
LT Debt / Equity
-0.1
-
-
EPS (TTM)
-0.02
EPS next Y
-
EPS next Q
-
EPS this Y
193.75%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
8.5%
Revenue last 5Y
75.25%
Revenue Q/Q
14.46%
EPS Q/Q
-38.1%
-
-
-
-
SMA20
-
SMA50
-33.33%
SMA100
-
Inst Own
0.01%
Inst Trans
1%
ROA
-943%
ROE
852%
ROC
10.32%
Gross Margin
87%
Oper. Margin
-407%
Profit Margin
-412%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.045-0.06
52W High
-
52W Low
-
RSI
37.47
Rel Volume
1.65
Avg Volume
1.58M
Volume
2.62M
Perf Week
-16.42%
Perf Month
-36.36%
Perf Quarter
-
Perf Half Y
-56.52%
-
-
-
-
Beta
7.13974
-
-
Volatility
0%, 0%
Prev Close
-10.83%
Price
0.014
Change
-11.17%
BPSR Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2020-10-31
| Metric | History | 2016-10-31 | 2017-10-31 | 2018-10-31 | 2019-10-31 | 2020-10-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0.01 | 0 | 0.01 | 0 | |
| Net income per share | -0.01 | -0.08 | -0.01 | -0.01 | -0.02 | |
| Operating cash flow per share | -0.01 | -0.01 | 0 | 0 | 0 | |
| Free cash flow per share | -0.01 | -0.01 | 0 | -120.44 | 0 | |
| Cash per share | 0 | 0 | 0 | 0 | 0 | |
| Book value per share | -0.01 | -0.03 | 0 | -0.01 | 0 | |
| Tangible book value per share | -0.01 | -0.03 | 0 | -0.01 | 0 | |
| Share holders equity per share | -0.01 | -0.03 | 0 | -0.01 | 0 | |
| Interest debt per share | 0 | 0.01 | 0 | -685.8 | 0 | |
| Market cap | 6.02M | 6.52M | 16.31M | 16.31M | 40.25M | |
| Enterprise value | 6.1M | 6.7M | 16.65M | -186.39B | 40.12M | |
| P/E ratio | -4.81 | -0.73 | -4.71 | -9.39 | -3.2 | |
| Price to sales ratio | 32.58 | 11.43 | 16.91 | 9.58 | 13.17 | |
| POCF ratio | -10.99 | -7.39 | -31.85 | -28.84 | -22.21 | |
| PFCF ratio | -10.48 | -7.03 | -31.57 | 0 | -20.63 | |
| P/B Ratio | -7.69 | -1.83 | -12.97 | -10.44 | -28.92 | |
| PTB ratio | -7.69 | -1.83 | -12.97 | -10.44 | -28.92 | |
| EV to sales | 32.97 | 11.75 | 17.26 | -109.5K | 13.13 | |
| Enterprise value over EBITDA | -4.92 | -0.8 | -5.16 | 111.22K | -3.24 | |
| EV to operating cash flow | -11.12 | -7.6 | -32.51 | 329.63K | -22.13 | |
| EV to free cash flow | -10.61 | -7.23 | -32.22 | 5.69 | -20.56 | |
| Earnings yield | -0.21 | -1.38 | -0.21 | -0.11 | -0.31 | |
| Free cash flow yield | -0.1 | -0.14 | -0.03 | -2.01K | -0.05 | |
| Debt to equity | -0.13 | -0.06 | -0.3 | 119.3K | -0.33 | |
| Debt to assets | 1.43 | 0.59 | 3.25 | -297.65K | 0.34 | |
| Net debt to EBITDA | -0.06 | -0.02 | -0.1 | 111.23K | 0.01 | |
| Current ratio | 0.04 | 0.07 | 0.08 | 0.18 | 0.33 | |
| Interest coverage | -81.96 | -15 | -15.29 | -38.12 | -69.98 | |
| Income quality | 0.44 | 0.1 | 0.15 | 0.33 | 0.14 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 15.88 | 4.4 | 1.87 | 4.94 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.05 | 0.05 | 0.01 | 57.89K | 0.08 | |
| Capex to revenue | -0.14 | -0.08 | 0 | -19.23K | -0.05 | |
| Capex to depreciation | -76.27 | -2.34 | -0.58 | -2.21M | -3.77 | |
| Stock based compensation to revenue | 0 | 10.22 | 4.17 | 0.43 | 3.24 | |
| Graham number | 0.05 | 0.25 | 0.04 | 0.03 | 0.03 | |
| ROIC | 1.53 | 2.62 | 4.31 | 0 | 18.92 | |
| Return on tangible assets | -17.93 | -23.81 | -29.58 | -2.77 | -9.43 | |
| Graham Net | -0.01 | -0.03 | 0 | -0.01 | 0 | |
| Working capital | -815.68K | -3.6M | -1.23M | -1.68M | -1.69M | |
| Tangible asset value | -783.07K | -3.5M | -1.21M | -1.56M | -1.39M | |
| Net current asset value | -815.68K | -3.6M | -1.23M | -1.83M | -1.88M | |
| Invested capital | -0.13 | -0.06 | -0.3 | 119.3K | -0.33 | |
| Average receivables | 10.5K | 58.04K | 81.49K | 37.03K | 27.71K | |
| Average payables | 177.09K | 420.52K | 534.52K | 514.63K | 659.04K | |
| Average inventory | 5.78K | 64.75K | 59.78K | 38.98K | 112.39K | |
| Days sales outstanding | 2.22 | 73.63 | 18.17 | 5.58 | 3.51 | |
| Days payables outstanding | 962.15 | 1.35K | 831.56 | 670.25 | 701.1 | |
| Days of inventory on hand | 38.45 | 271.67 | 0 | 94.59 | 134.43 | |
| Receivables turnover | 164.34 | 4.96 | 20.08 | 65.39 | 103.99 | |
| Payables turnover | 0.38 | 0.27 | 0.44 | 0.54 | 0.52 | |
| Inventory turnover | 9.49 | 1.34 | 0 | 3.86 | 2.72 | |
| ROE | 1.6 | 2.52 | 2.75 | 1.11 | 9.04 | |
| Capex per share | 0 | 0 | 0 | -120.44 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2021-07-31 for Q2
| Metric | History | 2020-07-31 | 2020-10-31 | 2021-01-31 | 2021-04-30 | 2021-07-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.61 | 0 | 0 | 0 | 0 | |
| Net income per share | -11.04 | -0.01 | -0.01 | 0 | 0 | |
| Operating cash flow per share | -0.67 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | -0.87 | 0 | 0 | 0 | 0 | |
| Cash per share | 0.67 | 0 | 0 | 0 | 0 | |
| Book value per share | -3.96 | 0 | 0 | 0 | 0 | |
| Tangible book value per share | -3.96 | 0 | 0 | 0 | 0 | |
| Share holders equity per share | -3.96 | 0 | 0 | 0 | 0 | |
| Interest debt per share | 1.17 | 0 | 0 | 0 | 0 | |
| Market cap | 28.59K | 44.12M | 57.99M | 63.18M | 66.13M | |
| Enterprise value | 254.75K | 43.98M | 58.34M | 63.6M | 66.66M | |
| P/E ratio | 0 | -2.14 | -1.78 | -7.05 | -11.73 | |
| Price to sales ratio | 0.04 | 44.87 | 42.38 | 52.87 | 48.35 | |
| POCF ratio | -0.09 | -52.59 | -120.13 | -55.66 | -131.5 | |
| PFCF ratio | -0.07 | -52.59 | -109.62 | -55.66 | -97.05 | |
| P/B Ratio | -0.02 | -31.7 | -20.15 | -25.09 | -26.85 | |
| PTB ratio | -0.02 | -31.7 | -20.15 | -25.09 | -26.85 | |
| EV to sales | 0.33 | 44.73 | 42.63 | 53.22 | 48.74 | |
| Enterprise value over EBITDA | -0.05 | -8.59 | -7.17 | -28.64 | -48.44 | |
| EV to operating cash flow | -0.8 | -52.43 | -120.85 | -56.02 | -132.56 | |
| EV to free cash flow | -0.62 | -52.43 | -110.28 | -56.02 | -97.83 | |
| Earnings yield | -183.92 | -0.12 | -0.14 | -0.04 | -0.02 | |
| Free cash flow yield | -14.43 | -0.02 | -0.01 | -0.02 | -0.01 | |
| Debt to equity | -0.29 | -0.33 | -0.14 | -0.24 | -0.23 | |
| Debt to assets | 0.48 | 0.34 | 0.47 | 0.47 | 0.33 | |
| Net debt to EBITDA | -0.04 | 0.03 | -0.04 | -0.19 | -0.39 | |
| Current ratio | 0.22 | 0.33 | 0.1 | 0.16 | 0.21 | |
| Interest coverage | -423.84 | -153.32 | -1.32K | -366.61 | -71.53 | |
| Income quality | 0.06 | 0.16 | 0.06 | 0.51 | 0.36 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 7.71 | 6.13 | 6.84 | 2.75 | 1.92 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.3 | 0 | 0.1 | 0 | 0.36 | |
| Capex to revenue | -0.12 | 0 | -0.03 | 0 | -0.13 | |
| Capex to depreciation | -8.9 | 0 | -3.79 | 0 | -13.6 | |
| Stock based compensation to revenue | 6.09 | 4.52 | 4.84 | 1.03 | 0.36 | |
| Graham number | 31.35 | 0.02 | 0.02 | 0.01 | 0.01 | |
| ROIC | 4.99 | 7.83 | 3.71 | 1.55 | 0.94 | |
| Return on tangible assets | -4.66 | -3.87 | -9.36 | -1.71 | -0.82 | |
| Graham Net | -5.38 | 0 | 0 | 0 | 0 | |
| Working capital | -2.18M | -1.69M | -3.23M | -2.98M | -3.1M | |
| Tangible asset value | -1.89M | -1.39M | -2.88M | -2.52M | -2.46M | |
| Net current asset value | -2.38M | -1.88M | -3.39M | -3.27M | -3.35M | |
| Invested capital | -0.29 | -0.33 | -0.14 | -0.24 | -0.23 | |
| Average receivables | 19M | 48.6K | 44.34K | 68.73K | 263.2K | |
| Average payables | 423.89M | 882.48K | 1.18M | 1.59M | 1.77M | |
| Average inventory | 80.97M | 154.67K | 147.62K | 151.19K | 198.66K | |
| Days sales outstanding | 7.95 | 2.69 | 3.9 | 5.89 | 29.49 | |
| Days payables outstanding | 891.29 | 684.29 | 848.57 | 1.06K | 1.28K | |
| Days of inventory on hand | 144.95 | 131.21 | 79.43 | 101.65 | 161 | |
| Receivables turnover | 11.32 | 33.46 | 23.08 | 15.29 | 3.05 | |
| Payables turnover | 0.1 | 0.13 | 0.11 | 0.09 | 0.07 | |
| Inventory turnover | 0.62 | 0.69 | 1.13 | 0.89 | 0.56 | |
| ROE | 2.79 | 3.71 | 2.83 | 0.89 | 0.57 | |
| Capex per share | -0.2 | 0 | 0 | 0 | 0 |
BPSR Frequently Asked Questions
What is Organicell Regenerative Medicine, Inc. stock symbol ?
Organicell Regenerative Medicine, Inc. is a US stock , located in Miami of Fl and trading under the symbol BPSR
What is Organicell Regenerative Medicine, Inc. stock quote today ?
Organicell Regenerative Medicine, Inc. stock price is $0.014 today.
Is Organicell Regenerative Medicine, Inc. stock public?
Yes, Organicell Regenerative Medicine, Inc. is a publicly traded company.
Company Profile
- Volume Average 1.58M
- Employee 18
- CEO Mr. Albert Mitrani
- Headquarters Miami,FL,US
- IPO Date 2022-01-31
-
Website
http://www.organicell.com 
Organicell Regenerative Medicine, Inc. processes, distributes, and supplies biologically processed cellular and tissue-based products in the United States. The company was formerly known as Biotech Products Services and Research, Inc. and changed its name to Organicell Regenerative Medicine, Inc. in June 2018. Organicell Regenerative Medicine, Inc. has an agreement with Regenerative Care Network to study potential therapeutic benefits of Zofin for patients with heart failure. Organicell Regenerative Medicine, Inc. was founded in 2011 and is headquartered in Miami, Florida.
